(E)-4-(3-hydroxypyrrolidin-1-yl)-N-methylbut-2-enamide

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (E)-4-(3-hydroxypyrrolidin-1-yl)-N-methylbut-2-enamide
• 化学式: C₉H₁₆N₂O₂
• 分子量: 184.24
• InChiKey: DJZYLBATYLOBJP-NSCUHMNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  52.6
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• [EN] COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS<br/>[FR] COMPOSÉS POUR INHIBER LA PROLIFÉRATION CELLULAIRE DANS LES CANCERS INDUITS PAR L'EGFR
  申请人：ARIAD PHARMA INC

  公开号：WO2013169401A1

  公开（公告）日：2013-11-14

  The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula (I), wherein the variables are as defined herein.

  这项发明涉及化合物、药物组合物和治疗EGFR驱动的Formula (I)癌症患者的方法，其中变量如本文所定义。
• [EN] SUBSTITUTED HETEROCYCLYL DERIVATIVES AS CDK INHIBITORS<br/>[FR] DÉRIVÉS HÉTÉROCYCLYLE SUBSTITUÉS EN TANT QU'INHIBITEURS DE CDK
  申请人：AURIGENE DISCOVERY TECH LTD

  公开号：WO2016193939A1

  公开（公告）日：2016-12-08

  The present invention provides substituted heterocyclylderivatives of formula (I), which are therapeutically useful, particularly as selective transcriptional CDK inhibitors including CDK7, CDK9, CDK12, CDK13 and CDK18, more particularly transcriptional CDK7 inhibitors. These compounds are useful in the treatment and prevention of diseases and/or disorders associated with selective transcriptional CDKs in a mammal. The present invention also provides preparation of the compounds and pharmaceutical formulations comprising at least one of the substituted heterocyclyl derivatives of formula (I) or a pharmaceutically acceptable salt or a stereoisomer thereof.

  本发明提供了公式（I）的取代杂环基衍生物，其在治疗上具有用途，特别是作为选择性转录CDK抑制剂，包括CDK7、CDK9、CDK12、CDK13和CDK18，更具体地是转录CDK7抑制剂。这些化合物在治疗和预防与哺乳动物中选择性转录CDK相关的疾病和/或疾病方面具有用途。本发明还提供了这些化合物的制备以及包含至少一种公式（I）的取代杂环基衍生物或其药学上可接受的盐或立体异构体的制药配方。
• METHODS AND COMPOSITIONS FOR RAF KINASE MEDIATED DISEASES
  申请人：ARIAD Pharmaceuticals, Inc.

  公开号：US20150166591A1

  公开（公告）日：2015-06-18

  The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula (I), wherein the variables are as defined herein.
• Compounds for Inhibiting Cell Proliferation in EGFR-Driven Cancers
  申请人：ARIAD Pharmaceuticals, Inc.

  公开号：US20160244469A1

  公开（公告）日：2016-08-25

  The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula I: wherein the variables are as defined herein.
• US9834571B2
  申请人：——

  公开号：US9834571B2

  公开（公告）日：2017-12-05